CA2397681A1 - Inhibiteurs calciques partiellement satures - Google Patents

Inhibiteurs calciques partiellement satures Download PDF

Info

Publication number
CA2397681A1
CA2397681A1 CA002397681A CA2397681A CA2397681A1 CA 2397681 A1 CA2397681 A1 CA 2397681A1 CA 002397681 A CA002397681 A CA 002397681A CA 2397681 A CA2397681 A CA 2397681A CA 2397681 A1 CA2397681 A1 CA 2397681A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
rings
heteroaromatic
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002397681A
Other languages
English (en)
Other versions
CA2397681C (fr
Inventor
Terrance P. Snutch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2397681A1 publication Critical patent/CA2397681A1/fr
Application granted granted Critical
Publication of CA2397681C publication Critical patent/CA2397681C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des composé représentés par la formule (1a) ou (1b) ou leurs sels, dans lesquelles chaque Z est indépendamment N ou CH, mais un Z doit être N; dans lesquelles n?1¿ est 1 et n?2¿ est 0 ou 1; X?1¿ et X?2¿ sont des segments de liaison; Ar représente un ou deux anneaux aromatiques ou hétéroaromatiques substitués ou non substitués, et Cy représente un ou deux anneaux aliphatiques cycliques ou hétérocycliques substitués ou non substitués, ou est composé d'un anneau aliphatique cyclique ou hétérocyclique substitué ou non substitué et d'un anneau aromatique ou hétéroaromatique substitué ou non substitué; Y¿a? et Y¿b? sont deux anneaux aromatiques ou hétéroaromatiques substitués ou non substitués, ou peuvent être deux anneaux aliphatiques cycliques ou hétérocycliques substitués ou non substitués, ou sont composés d'un anneau aliphatique cyclique ou hétérocyclique substitué ou non substitué et d'un anneau aromatique ou hétéroaromatique substitué ou non substitué; à condition que lesdits anneaux ne soient pas tous les deux un phényle lorsque les deux Ar comprennent un seul anneau de phényle et X?1¿ contient moins de 5C; et à condition que la formule (1b) contienne au moins un anneau aromatique ou hétéroaromatique; 1?1¿ est 0 ou 1; R?1¿ est un alkyle (1-6C) substitué ou non substitué, un aryle (6-10C) substitué ou non substitué ou un arylalkyle (7-16C) substitué ou non substitué contenant éventuellement 1-4 hétéroatomes sélectionnés dans le groupe composé de halo, N, P, O, et S ou pouvant être indépendamment halo, OR, SR, NR¿2?, OOCR, NROCR, COR, COOR, CONR¿2?, CF¿3?, CN ou NO¿2?, R étant H ou alkyle (1-6C).
CA2397681A 1999-12-20 2000-12-20 Inhibiteurs calciques partiellement satures Expired - Fee Related CA2397681C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17276599P 1999-12-20 1999-12-20
US60/172,765 1999-12-20
US47692999A 1999-12-30 1999-12-30
US09/476,929 1999-12-30
PCT/CA2000/001558 WO2001046166A2 (fr) 1999-12-20 2000-12-20 Inhibiteurs calciques partiellement satures

Publications (2)

Publication Number Publication Date
CA2397681A1 true CA2397681A1 (fr) 2001-06-28
CA2397681C CA2397681C (fr) 2011-03-15

Family

ID=26868438

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2397681A Expired - Fee Related CA2397681C (fr) 1999-12-20 2000-12-20 Inhibiteurs calciques partiellement satures

Country Status (7)

Country Link
EP (1) EP1242398A2 (fr)
JP (1) JP2003518107A (fr)
AU (1) AU784848B2 (fr)
CA (1) CA2397681C (fr)
MX (1) MXPA02006137A (fr)
NO (1) NO326939B1 (fr)
WO (1) WO2001046166A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031227A1 (fr) * 2006-09-14 2008-03-20 Neuromed Pharmaceuticals Ltd. Composés de diaryle piperidine utilisés en tant que bloqueurs de canaux calciques

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004233863B2 (en) 2003-04-24 2010-06-17 Incyte Holdings Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
EP1558582B1 (fr) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Derives de diaryl et arylheteroaryl uree utilises en tant que modulateurs du recepteur de la serotonine 5-ht2a utiles pour la prophylaxie et le traitement de troubles associes a ce dernier
AU2005254800B2 (en) 2004-06-15 2010-12-09 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
KR20070063526A (ko) 2004-08-30 2007-06-19 뉴로메드 파머큐티칼즈 리미티드 칼슘 채널 차단제인 우레아 유도체
US7511077B2 (en) 2005-02-09 2009-03-31 Neuromed Pharmaceuticals Ltd. Diamine calcium channel blockers
NZ556627A (en) 2005-02-22 2010-09-30 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
US9567327B2 (en) 2007-08-15 2017-02-14 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (fr) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Procédés utiles pour la préparation de 1-[3-(4-bromo-2-méthyl-2h-pyrazol-3-yl)-4-méthoxy-phényl]-3-(2,4-difluoro‑phényl)-urée, et formes cristallines associées
TR201805216T4 (en) 2008-10-28 2018-06-21 Arena Pharm Inc COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
US9365553B2 (en) 2010-05-27 2016-06-14 Aska Pharmaceutical Co., Ltd. Heterocyclic compound and H1 receptor antagonist
EP3288926B1 (fr) 2015-04-28 2021-01-20 Unilever PLC Composés d'aralkylcarboxamido-piperazine et -homopiperazine et des compositions de soins personnels comprenant ceux-ci
CN107548387B (zh) 2015-04-28 2020-08-25 荷兰联合利华有限公司 N-芳烷基羰基二胺化合物以及包含它们的个人护理组合物
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
WO2017011767A2 (fr) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Dérivés d'arylhérétoaryl urée en tant que modulateurs du récepteur sérotoninergique 5-ht2a utiles pour la prophylaxie et le traitement d'hallucinations associées à une maladie neurodégénérative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703071A (en) * 1990-08-29 1997-12-30 Pharmacia & Upjohn Company Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases
DE4111861A1 (de) 1991-04-11 1992-10-15 Schwabe Willmar Gmbh & Co Benzopyranone, verfahren zu ihrer herstellung und verwendung
WO1992020661A1 (fr) * 1991-05-22 1992-11-26 Merck & Co., Inc. N, n-diacylpiperazines
PT682664E (pt) 1993-12-08 2001-06-29 Alcon Laboratoires Inc Compostos possuindo actividade potente como antagonistas do calcio e anti-oxidantes e sua utilizacao como agentes citoprotectores
DE69814089T2 (de) * 1997-06-16 2004-02-19 Janssen Pharmaceutica N.V. Verwendung von einem draflazin analog zur schmerzbehandlung
US6251919B1 (en) * 1998-02-27 2001-06-26 Warner-Lambert Heterocyclic substituted aniline calcium channel blockers
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031227A1 (fr) * 2006-09-14 2008-03-20 Neuromed Pharmaceuticals Ltd. Composés de diaryle piperidine utilisés en tant que bloqueurs de canaux calciques

Also Published As

Publication number Publication date
NO326939B1 (no) 2009-03-16
MXPA02006137A (es) 2002-12-05
AU784848B2 (en) 2006-07-06
WO2001046166A2 (fr) 2001-06-28
WO2001046166A3 (fr) 2002-03-07
CA2397681C (fr) 2011-03-15
JP2003518107A (ja) 2003-06-03
AU2495701A (en) 2001-07-03
NO20022948D0 (no) 2002-06-19
NO20022948L (no) 2002-08-19
EP1242398A2 (fr) 2002-09-25

Similar Documents

Publication Publication Date Title
CA2335461A1 (fr) Inhibiteur des canaux calciques
KR101677790B1 (ko) 키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제
AU2013214783B2 (en) CDK8/CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
Staal et al. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata
KR101762999B1 (ko) 종양 치료제
EA200100766A1 (ru) Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов
TR199801530T2 (xx) VEGF �nhibit�rleri olarak kinazolin t�revleri.
RU2007110629A (ru) Ингибиторы днк-пк
RU2000127751A (ru) Противоопухолевое средство
CA2478094A1 (fr) Procedes d'induction de differenciation terminale
HUP0301427A2 (hu) Fotokemoterápiában alkalmazható fotoszenzitizáló, 5-aminolevulinsavészterek azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
EP2141155A1 (fr) Agent prophylactique et/ou thérapeutique contre l'hyperlipémie
BR9905788A (pt) Derivados de 2-(2-oxo-etilideno)-imidazolidin-4-ona e composições e métodos para a inibição do crescimento de célula anormal que compreendem os referidos derivados
RU2012123009A (ru) Применение бензогетероциклических производных для предупреждения и лечения рака или для ингибирования метастазирования рака
NO167510B (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fenylkinolincarboxylsyrer
MY125099A (en) Comminuted form of (s)-2-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) penyl] propanoic acid
JP2024509265A (ja) 赤血球増加症を処置するための組成物および方法
EA200400896A1 (ru) Терапевтические акридоновые и акридиновые соединения
CN106957315A (zh) N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
US20200215068A1 (en) Treatment of type i and type ii diabetes
KR100776184B1 (ko) 치환된 아크릴로일 디스타마이신 유도체를 포함하는, 고수준의 글루타티온과 관련된 종양 치료용 약제학적 조성물
RU95107147A (ru) Производные циклогексанкарбоновой кислоты, смесь их изомеров или отдельные изомеры и физиологически переносимые соли и фармацевтическая композиция с тормозящей ферментный комплекс глюкоза-6-фосфатазы печени активностью
US20240409510A1 (en) Compounds for the treatment of sars
CA2391915A1 (fr) Composes de 3-phenyl-3,7-diazabicyclo[3.3.1]nonane, procede pour leur preparation et medicament contenant ces composes
WO2020055946A1 (fr) Ciblage de l'egln1 dans le cancer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141222